These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35677166)

  • 21. Clinical and prognostic role of interim 18F-FDG PET/CT in elderly Hodgkin lymphoma: a dual-center experience.
    Albano D; Mazzoletti A; Zilioli VR; Muzi C; Crucitti L; Tucci A; Pagani C; Re A; Rossetti C; Giubbini R; Bertagna F
    Leuk Lymphoma; 2020 Dec; 61(13):3209-3216. PubMed ID: 32705908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different predictive values of interim
    Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
    Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of
    Ying Z; Mi L; Zhou N; Wang X; Yang Z; Song Y; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Zhang C; Liu W; Deng L; Zhu J
    Chin J Cancer Res; 2019 Feb; 31(1):162-170. PubMed ID: 30996574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Values of Baseline
    Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
    Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
    Schöder H; Zelenetz AD; Hamlin P; Gavane S; Horwitz S; Matasar M; Moskowitz A; Noy A; Palomba L; Portlock C; Straus D; Grewal R; Migliacci JC; Larson SM; Moskowitz CH
    J Nucl Med; 2016 May; 57(5):728-34. PubMed ID: 26719374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prognostic Value of
    Su JM; Zheng QZ; Huang WR; Deng J; Wu J; Lu HQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1181-1186. PubMed ID: 34362500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
    Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
    Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment
    Györke T; Carr R; Cerci JJ; Meneghetti C; Redondo F; Celli M; Gorospe C; Auewarakul CU; Jorgov L; Paez D; Fanti S
    J Nucl Med; 2020 Jul; 61(7):999-1005. PubMed ID: 31757842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome.
    Wang F; Cui S; Lu L; Shao X; Yan F; Liu Y; He B; Wang J; Cao Y; Yue Y; Wang Y; Gu W
    BMC Cancer; 2023 Nov; 23(1):1165. PubMed ID: 38030989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUV
    Rekowski J; Hüttmann A; Schmitz C; Müller SP; Kurch L; Kotzerke J; Franzius C; Weckesser M; Bengel FM; Freesmeyer M; Hertel A; Krohn T; Holzinger J; Brink I; Haberkorn U; Nyuyki F; van Assema DME; Geworski L; Hasenclever D; Jöckel KH; Dührsen U
    J Nucl Med; 2021 Jan; 62(1):37-42. PubMed ID: 32385164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of negative interim 2-[¹⁸F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma.
    Kwon SH; Kang DR; Kim J; Yoon JK; Lee SJ; Jeong SH; Lee HW; An YS
    Clin Radiol; 2016 Mar; 71(3):280-6. PubMed ID: 26732889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma.
    Baratto L; Davidzon GA; Moghbel M; Hatami N; Iagaru A; Mittra ES
    Clin Nucl Med; 2018 Jan; 43(1):1-8. PubMed ID: 29076913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progression Free Survival and Predictor of Recurrence in DLBCL patients with Negative Interim 18FDG PET/CT Using Standardized Imaging and Reporting Protocols.
    Zaman MU; Fatima N; Zaman A; Zaman U; Zaman S; Tahseen R
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2343-2348. PubMed ID: 32856864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interim FDG-PET/CT for Response Assessment of Lymphoma.
    Zeman MN; Akin EA; Merryman RW; Jacene HA
    Semin Nucl Med; 2023 May; 53(3):371-388. PubMed ID: 36376131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic tumor volume changes assessed by interval
    Oñate-Ocaña LF; Cortés V; Castillo-Llanos R; Terrazas A; Garcia-Perez O; Pitalúa-Cortes Q; Ponce M; Dueñas-Gonzalez A; Candelaria M
    Oncol Lett; 2018 Aug; 16(2):1411-1418. PubMed ID: 30008818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic Value of Interim PET/CT in 227 Patients of DLBCL].
    Wang RM; Li F; Liu CB; Guan ZW; Fu LP; Xu BX; Zhu HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):74-79. PubMed ID: 30738450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
    Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
    J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma.
    Fuertes S; Setoain X; Lopez-Guillermo A; Carrasco JL; Rodríguez S; Rovira J; Pons F
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):496-504. PubMed ID: 23344136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of total lesion glycolysis and cell-of-origin subtypes for prognostic stratification of diffuse large B-cell lymphoma patients.
    Jiang C; Teng Y; Zheng Z; Zhou Z; Xu J
    Quant Imaging Med Surg; 2021 Jun; 11(6):2509-2520. PubMed ID: 34079720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.